Mats Wahlstrom's Insider Trades & SAST Disclosures
Mats Wahlstrom's most recent trade in TriSalus Life Sciences Inc was a trade of 44,750 Series A Convertible Preferred Stock done . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mats Wahlstrom.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TriSalus Life Sciences Inc | Mats L. Wahlstrom | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 10 Feb 2025 | 44,750 | 94,750 | - | - | Series A Convertible Preferred Stock | |
| TriSalus Life Sciences Inc | Mats L. Wahlstrom | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 3.97 per share. | 17 Dec 2024 | 25,188 | 40,915 | - | 4.0 | 99,996 | Common Stock |
| TriSalus Life Sciences Inc | Mats L. Wahlstrom | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.55 per share. | 22 Nov 2024 | 5,000 | 15,727 | - | 4.6 | 22,750 | Common Stock |
| TriSalus Life Sciences Inc | Mats L. Wahlstrom | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.44 per share. | 20 Nov 2024 | 8,687 | 10,727 | - | 4.4 | 38,570 | Common Stock |
| TriSalus Life Sciences Inc | Mats L. Wahlstrom | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.16 per share. | 20 Nov 2024 | 2,040 | 2,040 | - | 4.2 | 8,486 | Common Stock |
| TriSalus Life Sciences Inc | Mats L. Wahlstrom | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 15,000 | 15,000 | - | - | Director stock option (right to buy) | |
| Coherus Biosciences Inc | Mats L. Wahlstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 112,000 | 112,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Wahlstrom L. Mats | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 99,988 | 0 (0%) | 0% | 0 | Common Stock | |
| Coherus Biosciences Inc | Wahlstrom L. Mats | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 99,988 | 99,988 (0%) | 0% | 0 | Common Stock | |
| Coherus Biosciences Inc | Mats Wahlstrom L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.67 per share. | 01 Feb 2024 | 44,991 | 99,988 (0%) | 0% | 1.7 | 75,000 | Common Stock |
| Coherus Biosciences Inc | Mats L. Wahlstrom | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 44,991 | 0 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | L. Wahlstrom Mats | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 14,997 | 0 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Wahlstrom L. Mats | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.67 per share. | 01 Feb 2024 | 14,997 | 54,997 (0%) | 0% | 1.7 | 25,000 | Common Stock |
| TriSalus Life Sciences Inc | Mats L. Wahlstrom | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Coherus Biosciences Inc | Mats L. Wahlstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 38,250 | 38,250 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Mats Wahlstrom | Director | Grant, award, or other acquisition of securities at price $ 2.08 per share. | 25 Feb 2022 | 29,994 | 40,000 (0%) | 0% | 2.1 | 62,501 | Common Stock |
| Coherus Biosciences Inc | Mats Wahlstrom | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 29,994 | 0 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Mats Wahlstrom | Director | Grant, award, or other acquisition of securities at price $ 11.64 per share. | 25 Feb 2022 | 10,006 | 10,006 (0%) | 0% | 11.6 | 116,433 | Common Stock |
| Coherus Biosciences Inc | Mats Wahlstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 27,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Mats Wahlstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Mats Wahlstrom | Director | Sale of securities on an exchange or to another person at price $ 17.15 per share. | 17 Jun 2020 | 200,000 | 0 (0%) | 0% | 17.2 | 3,430,020 | Common Stock, $0.0001 par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges